N-(2-Chlor-phenylsulfonyl)iminodithiokohlensaeuredimethylester | 84346-43-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-Chlor-phenylsulfonyl)iminodithiokohlensaeuredimethylester
• 英文别名: dimethyl N-<(2-chlorophenyl)sulfonyl>dithiocarbonimidate；[(2-chlorophenyl)sulfonyl]dithioimidocarbonic acid dimethyl ester；N--2-chlorobenzenesulfonamide；dimethyl ((2-chlorophenyl)sulfonyl)carbonimidodithioate；N-(bis-methylsulfanyl-methylene)-2-chloro-benzenesulfonamide；N-(bis-methylsulfanylmethylidene)-2-chlorobenzenesulfonamide；dimethyl N-(2-chlorophenylsulfonyl)carbonimidodithioate；N-[bis(methylsulfanyl)methylidene]-2-chlorobenzenesulfonamide
• CAS: 84346-43-0
• 化学式: C₉H₁₀ClNO₂S₃
• 分子量: 295.835
• InChiKey: VXOVCNNGZSSVEY-UHFFFAOYSA-N

物化性质

• 熔点：
  121-122 °C(Solv: methanol (67-56-1))
• 沸点：
  440.5±47.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  106
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(2-Chlor-phenylsulfonyl)iminodithiokohlensaeuredimethylester 生成 2-chloro-N-(dichloromethylidene)benzenesulfonamide
  参考文献：
  名称：

  FEST, CHRISTA;RIEBEL, HANS-JOCHEM;SANTEL, HANS-JOACHIM;SCHMIDT, ROBERT R.+

  摘要：

  DOI：
• 作为产物：
  描述：

  邻氯苯磺酰胺 在 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.58h， 生成 N-(2-Chlor-phenylsulfonyl)iminodithiokohlensaeuredimethylester
  参考文献：
  名称：

  McFadden, Helen G.; Huppatz, John L.; Halladay, Peter K., Australian Journal of Chemistry, 1993, vol. 46, # 6, p. 873 - 886

  摘要：

  DOI：

文献信息

• Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB₁ Cannabinoid Receptor Antagonists
  作者：Jos H. M. Lange、Hein K. A. C. Coolen、Herman H. van Stuivenberg、Jessica A. R. Dijksman、Arnoud H. J. Herremans、Eric Ronken、Hiskias G. Keizer、Koos Tipker、Andrew C. McCreary、Willem Veerman、Henri C. Wals、Bob Stork、Peter C. Verveer、Arnold P. den Hartog、Natasja M. J. de Jong、Tiny J. P. Adolfs、Jan Hoogendoorn、Chris G. Kruse

  DOI：10.1021/jm031019q

  日期：2004.1.1

  novel 3,4-diarylpyrazolines was synthesized and evaluated in cannabinoid (hCB(1) and hCB(2)) receptor assays. The 3,4-diarylpyrazolines elicited potent in vitro CB(1) antagonistic activities and in general exhibited high CB(1) vs CB(2) receptor subtype selectivities. Some key representatives showed potent pharmacological in vivo activities after oral dosing in both a CB agonist-induced blood pressure

  合成了一系列新颖的3,4-二芳基吡唑啉并在大麻素（hCB（1）和hCB（2））受体测定中进行了评估。3,4-diarylpyrazolines引起有效的体外CB（1）拮抗活性，并通常表现出高CB（1）vs CB（2）受体亚型选择性。一些关键代表在CB激动剂诱导的血压模型和CB激动剂诱导的体温过低模型中，口服给药后均显示出强大的体内药理活性。外消旋体67的手性分离，然后进行结晶和X射线衍射研究，阐明了Eutomer 80（SLV319）在其C（4）位置的绝对构型为4S。生物分析研究显示，候选发育80的中枢神经系统血浆比例很高。分子建模研究表明80与已知的CB（1）受体拮抗剂利莫那班（SR141716A）之间存在相对紧密的三维结构重叠。对80的X射线衍射数据的进一步分析表明，存在分子内氢键，这已通过计算方法得到了证实。计算模型和X射线衍射数据表明体内非活性化合物6中分子内氢键的模式不同。此外，
• Fused [1,2,4]oxadiazolylidenebenzenesulfonamides and their use as
  申请人：E. I. Du Pont de Nemours & Co.

  公开号：US04411690A1

  公开（公告）日：1983-10-25

  Fused [1,2,4]oxadiazolylidenebenzenesulfonamides such as 2-chloro-N-(5,7-dimethyl-2H-[1,2,4]oxadiazolo-[2,3-a]pyrimidin-2-ylidene)b enzenesulfonamide and 2-chloro-N-(7-methoxy-5-methyl-2H-[1,2,4]oxadiazolo-[2,3-a][1,3,5]triazin- 2-ylidene)benzenesulfonamide are general and selective pre- or post-emergence herbicides and can be useful in regulating plant growth.

  氧代二唑基苯磺酰胺类化合物，如2-氯-N-(5,7-二甲基-2H-[1,2,4]氧代二唑基[2,3-a]嘧啶-2-基)苯磺酰胺和2-氯-N-(7-甲氧基-5-甲基-2H-[1,2,4]氧代二唑基[2,3-a][1,3,5]三嗪-2-基)苯磺酰胺是一般和选择性的前期或后期除草剂，可用于调节植物生长。
• Discovery, Synthesis, and Evaluation of Small-Molecule Signal Transducer and Activator of Transcription 3 Inhibitors
  作者：Zhi-Bing Shi、Dan Zhao、Yan-Yan Huang、Yun Du、Xiang-Rong Cao、Zhu-Nan Gong、Rui Zhao、Jian-Xin Li

  DOI：10.1248/cpb.c12-00745

  日期：——

  The signal transducer and activator of transcription 3 (STAT3) oncogene is a promising molecular target and its inhibitors have great potential as anticancer drugs. To identify novel and STAT3-selective inhibitors, a virtual screening based on Specs and Maybridge databases was conducted and a 6,6'-bibenzoxazole type small molecule, compound 3a with a inhibition constant K(i) value of 494.32 nM to STAT3

  转录3（STAT3）癌基因的信号转导和激活剂是一种有前途的分子靶标，其抑制剂作为抗癌药物具有巨大的潜力。为了鉴定新型和STAT3选择性抑制剂，基于Specs和Maybridge数据库进行了虚拟筛选，并探索了对STAT3的抑制常数K（i）为494.32 nM的6,6'-联苯并恶唑型小分子化合物3a。 。此外，使用人乳腺癌细胞系MDA-MB-468和MCF-7分别具有或不具有STAT3的组成性表达，通过基于细胞的分析合成并评估了最初衍生自3a的一系列新衍生物。在该系列中，3a，3c，3d和4e表现出更好的抑制活性和良好的选择性。其中，3a和3c显着抑制STAT3蛋白水平，并且还显示出对STAT3的结合亲和力，该流动性分析用石英晶体微天平（FIA-QCM）分析系统检测到。结果为有效的STAT3抑制剂的未来设计和开发提供了新的线索。
• SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Van Loevezijn Arnold

  公开号：US20080311179A1

  公开（公告）日：2008-12-18

  This invention concerns compounds of the general formula (1). and derivatives thereof, which are antagonists of 5-HT 6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes.

  本发明涉及通式（1）的化合物及其衍生物，它们是5-HT6受体拮抗剂，其中符号的含义如说明书所示。本发明还涉及制备这些化合物的方法，对于其合成有用的新型中间体，以及这些化合物和组合物的用途，特别是将它们用于向患者施用以达到治疗帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知衰退、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安定症、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓损伤或头部损伤有关的疾病、脑积水、功能性肠道障碍、肠易激综合征、肥胖症和2型糖尿病等至少一种疾病或症状的治疗效果。
• Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists
  申请人：Solvay Pharmaceuticals B.V.

  公开号：US07728018B2

  公开（公告）日：2010-06-01

  This invention concerns compounds of the general formula (1): and derivatives thereof, which are antagonists of 5-HT6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes.

  这项发明涉及一般式（1）的化合物及其衍生物，它们是5-HT6受体的拮抗剂，其中符号具有描述中所给出的含义。该发明还涉及制备这些化合物的方法，对于其合成有用的新中间体，以及这些化合物和组合物的用途，特别是将它们用于给患者治疗至少一种疾病或病状，包括帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑症、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知衰退、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安躁动、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓损伤或头部损伤相关的疾病、脑积水、功能性肠道紊乱、肠易激综合征、肥胖症和2型糖尿病。